Good news and bad news on the second year of the presidential cycle. Outlook Presidential cycle playbook: ‘Mid-term mayhem’ and a Q4 rally?
Biotech stocks tend to outperform in times of economic expansion. Strategies Why I added Amgen and Celgene to my portfolio
Lower energy costs are boosting corporate cash flows. Strategies On the hunt for cash-spinning companies with a competitive edge
Market choppiness will be the norm not exception. Strategies Get ready for more stock market volatility
